Smoke-Free Living Study

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to provide you with an effective treatment for reducing the physical and emotional stress that can occur during the early phase of being without cigarettes. It is our hope that this treatment will help you to stay smoke-free. You will receive counseling and a supply of Champix, a medication to help suppress the symptoms of nicotine withdrawal.

Purpose: To assess the effect of extended Integrated Voice Response (IVR) on smoking cessation after varenicline (Champix) and IVR treatment Hypothesis: There will be significant increase in participants who do not smoke at 1 year if extended IVR is used after 12 weeks of varenicline (Champix) and IVR treatment.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of British Columbia
• Collaborator: Pfizer
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• Smoking 35 or more cigarettes per week or 5 or more cigarettes per day,

• Smoking for at least 2 years, with no period of abstinence longer than 3 months.

Exclusion Criteria:

• Using any smoking cessation drugs or nicotine replacement drugs in the last 3 months,

• Use of medication to treat depression or any psychiatric illness,

• Impaired renal function,

• Unstable medical condition,

• Pregnancy or breast feeding.